logo
  

AXA To Sell Insurance Operations In Romania - Update

French insurer Axa SA (AXAHY.PK) Thursday said it has agreed with Certinvest and SIF Transilvania to sell its Life & Savings insurance operations in Romania and exit the Romanian market. The parties agreed not to disclose the terms and conditions of the deal.

As per the terms of the agreement, Certinvest would acquire a 70 percent stake in AXA's Romanian division, AXA Life Insurance S.A., while SIF Transilvania would acquire the remaining stake of 30 percent.

Certinvest is an independent asset manager in Romania. SIF Transilvania is a financial investment firm listed on the Bucharest Stock Exchange.

Completion of the deal is subject to customary closing conditions, including receipt of regulatory approvals.

Earlier last month, Principal Financial Group, Inc. (PFG) agreed to acquire Axa's Mandatory Provident Fund and Occupational Retirement Schemes Ordinance pension business in Hong Kong for about $335 million. The transaction is expected to close in the third quarter of 2015.

Last month end, Axa had entered into an agreement to buy 100 percent of Assur Africa Holdings for a total cash consideration of 198 million euros. Assure Africa holds 77 percent stake in Nigeria's composite insurance company Mansard Insurance Plc.

In Paris, Axa shares are currently trading at 18.79 euros, up 3.07 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT